There’s a little problem, though: most of the decline in the seven comes down to one company. Apple is down 14 per cent since ...

U.S. drugmaker Pfizer PFE.N is going “all in” to develop its experimental obesity drug and has been recruiting more experts in that area, Chief Executive Officer Albert Bourla said at the JPMorgan ...

Altimmune, Inc. (NASDAQ:ALT), a biopharmaceutical company with a market capitalization of $503.56 million focused on ...

Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new drug last month and ...

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.

Socially responsible companies are businesses that integrate social and environmental considerations into their core operations and decision-making processes.

Medications such as Ozempic can reduce the risk of a range of different diseases and health conditions but also increase the ...

Join Fox News for access to this content Plus special access to select articles and other premium content with your account - ...

Jefferies analyst Roger Song maintained a Buy rating on Viking Therapeutics (VKTX – Research Report) yesterday and set a price target of ...

There are several potential challengers to Novo Nordisk and Eli Lilly’s obesity drugs, and Jefferies analysts see one as particularly promising.

GLP-1 agonists for weight loss are now commonly used for adults, but might they also be an effective treatment for younger people? Katharine Lang reports Obesity in children and adolescents is a ...